

# **Report from the ASGT Ad Hoc Committee on Retroviral-mediated Gene Transfer to Hematopoietic Stem Cells**

**April, 2003**

## **Clinical Trials of Gene Transfer to Hematopoietic Stem Cells by Retroviral Vectors**

### **References**

1. Brenner, MK, Rill, DR, Moen, RC, Krance, RA, Mirro Jr, J, Anderson, WF, Ihle, JN. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. *Lancet*. 341:85-86 (1993).
2. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santanta VM, Anderson WF, and Ihle JN. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. *Lancet* 342:1134-1137, 1993.
3. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, and Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. *Blood* 84:380-383, 1994.
4. Dunbar CE, Cottler-Fox, M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson WH, Cowan K, Young NS, and Nienhuis AW. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. *Blood* 85:3048-3057, 1995.
5. Emmons R.V.B., Doren S., Zujewski J., Cottler-Fox M., Carter C.S., Hines K., O'Shaughnessy J.A., Leitman S.F., Greenblatt J.J., Cowan K., Dunbar C.E. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for 6 hours without growth factors or an autologous stroma does not improve marking efficiency assessed in vivo. *Blood*. 89:4040-4046, 1997.
- 5A. Cornetta, K., Srour, E.F., Moore, A., Davidson, A., Broun, E. R., Hromas, R., Moen, R. C., Morgan, R.A., Rubin, L., Anderson, W. F., Hoffman, R., and Tricot, G. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. *Human Gene Therapy* 7:1323-1329, 1996.
6. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, and Reading C. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. *Blood* 83:3068-3076, 1994.

7. Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth AB. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. *Leuk Lymphoma* 32:279-288, 1999.
8. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, et al. Retroviral-mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. *Hum Gene Ther* 5:891-911, 1994.
9. Cowan K.H., Moscow J.A., Huang H., Zujewski J., O'Shaughnessy J., Sorrentino B., Carter C., Schneider E., Cusack G., Noone M., Dunbar C., Steinberg S., Wilson W., Goldspiel B., Read E.J., Leitman S., McDonagh K., Chow C., Abati A., Chiang Y., Weir S., Gottesman M., Pastan I., and Nienhuis A.W. Paclitaxel chemotherapy following autologous stem cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance cDNA (MDR1) in metastatic breast cancer patients. *Clin. Cancer Res.* 5:1619-1628, 1999.
10. Moscow J.A., Huang H., Sorrentino B., Zujewski J., Chiang Y., Chang Y.N., Cullen E., Cusack G., Carter C., Hines K., Goldspiel B., Leitman S., Read E.J., Abati A., Venzon D., Sellers S., Gottesman M., Pastan I., Dunbar C., Cowan K.H. Effect of MDR1 gene transduction on engraftment and expansion of hematopoietic progenitor cells during breast cancer chemotherapy. *Blood*. 94:52-61, 1999.
11. Kavanagh J, Hanania E, Giles R, Fu SQ, Zu Z, Ellerson D, Wang T, Claxton D, Rahman Z, Berenson R, Heimfeld S, Cote R, Holzmayer T, Mechetner E, Dayne A, Andreeff M, Champlin R, and Deisseroth AB. Genetic modification of cells used for transplant following intensive therapy for ovarian cancer and breast cancer. *Blood* 88 (Suppl 1): 272a, 1996.
12. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin R, and Deisseroth AB. Results of MDR-1 vector modification trial indicates that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. *Proc Natl Acad Sci (USA)* 93:15346-15351, 1996.
13. Devereux S, Corney C, Macdonald C, Watts M, Sullivan A, Goldstone AH, Ward M, Bank A, and Linch DC. Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma. *Gene Ther* 5:403-408, 1998.
14. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, and Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. *J Clin Oncol*, 16:165-172, 1998.

15. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coffman J, Traycoff CM, Bank A, Kato I, Ward M, Williams SD, Hromas R, Robertson MJ, Smith FO, Woo D, Mills B, Srour EF, and Cornetta K. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. *Nat Med* 2000 Jun;6(6):652-8
16. Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, Miller M, Ely J, and Gerlach W. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. *Hum Gene Ther* 10:2255-70, 1999.
17. Amado RG, Mitsuyasu RT, Ngok FK, et al. Multilineage Engraftment and Preferential Survival of Ribozyme Containing CD4+ T-Lymphocytes Derived from CD34+ Progenitor Cells in a Phase I Study in HIV-1. *American Society of Gene Therapy 5<sup>th</sup> annual meeting 2002; June.*
18. Zaia JA, Rossi JJ, Krishnan A, et al. Autologous stem cell transplantation using retrovirus-transduced peripheral blood progenitor cells in HIV-infected persons: comparison of gene marking post-engraftment with and without myeloablative therapy. *Blood* 1999;94 (suppl): S642a.
19. Kohn DB, Bauer GH, Valdez P, et al. A clinical trial of retroviral-mediated transfer of an RRE Decoy gene into CD34+ cells from the bone marrow of HIV-1 infected children. *Blood* 1999;94: 368-371.
20. Liu D, Conant MA, Cowan MJ, et al. Engraftment and Development of HGTV43-Transduced CD34<sup>+</sup> PBSC in HIV-1 Seropositive Individuals. *American Society of Gene Therapy 5<sup>th</sup> annual meeting 2002; June.*
21. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. *Science* 1995;270: 470-475.
22. Hoogerbrugge PM, van Beusechem VW, Fisher A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. *Gene Therapy* 1996;3:179-183.
23. Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency. *Nature Medicine* 1995;1:1017-1026.
24. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. *Nat Med* 1998;4: 775-780.
25. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. *Science* 2002;296: 2410-2413.
26. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science* 2000;288: 669-672.
27. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *N Engl J Med* 2002;346: 1185-1193.

28. Bauer TR Jr, Hickstein DD. Gene therapy for leukocyte adhesion deficiency. *Curr Opin Mol Ther* 2000;2: 383-388.
29. Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. *Proc Natl Acad Sci (USA)* 1997;94: 12133-12138.
30. Malech H, et al: *Mol Ther* 1:S101, 2000;
31. Choi U, Malech H: *Blood* 96:805a, 2000;
32. Malech HL: *J Inf Dis* 179 (Suppl 2):S318-S325
33. Dunbar CE, Kohn DB, Schiffmann R, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. *Hum Gene Ther* 1998;9: 2629-2640.
34. Barranger JA, Rice E, Dunigan J, et al. Approaches to gene therapy of Gaucher disease. *Cold Spring Harbor Symposium on Gene Therapy*, September 1996.
35. Schuening F, Longo WL, Atkinson ME, et al. Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease. *Hum Gene Ther* 1997;8: 2143-2160.
36. Liu JM, Kim S, Read EJ, et al. Engraftment of hematopoietic progenitor cells Fanconi Anemia Group C Gene (FANCC). *Hum Gene Ther* 1999;10: 2337-2346.